About the CPCT
Since 2010 three of the largest cancer centers in the Netherlands – the Netherlands Cancer Institute-Antoni van Leeuwenhoek, Erasmus MC Cancer Institute and UMC Utrecht – have been combining their DNA-focused cancer research in the Center for Personalized Cancer Treatment (CPCT). By pooling and centralizing our activities, we can accelerate the realization of research standardization; an indispensable foundation for performing sound clinical research and developing new treatment strategies for cancer.
Since the establishment of CPCT, many hospitals have joined the initiative, including all academic hospitals and many non-academic hospitals in the Netherlands. In 2016 we also started working with the Hartwig Medical Foundation, which realizes the sequencing activities that provide insight into the DNA by Whole Genome Sequencing (see www.hartwigmedicalfoundation.nl for more information).
Treatment of cancer is currently based on the ‘average cancer treatment’. As a result, the treatment of, for example, lung or breast cancer is effective for some but not all patients. Meanwhile, all patients suffer from the side effects of the treatment.
Every (type of) cancer has different characteristics and properties in each patient. It is only logical therefore to base treatment on individual cases rather than ‘the average cancer patient’. Not general treatment but personalized. Impossible? No. The CPCT is dedicated to realizing more effective, individual cancer treatment. In the future, each patient will have a ‘custom’ treatment plan with the best possible treatment for the individual in question.
CPCT aims to offer every patient personalized treatment for cancer, based on the genetic properties of the patient’s tumor. In doing so, we strive to avoid inefficient treatment.
Our three core activities
- Identifying known genetic changes in the DNA of the individual tumor, which are associated with outcome to treatment and in the future can serve as a guideline for the cancer treatment.
- Carrying out research into new genetic defects that can predict the efficiency of a treatment.
- Performing clinical scientific research in which we test (new) medication in selected patients.